Skip to main content
Premium Trial:

Request an Annual Quote

BD Biosciences, PerkinElmer, Caliper, Artel

Premium

BD Biosciences Revenue Grows 10 Percent in Fiscal Q1 on Strong Reagent, Instrument Sales

Becton Dickinson this week said that fiscal first-quarter revenue for its Biosciences division grew more than 10 percent while overall receipts at the life sciences company increased 10 percent as well.

Total receipts for the Biosciences unit during the three months ended Dec. 31, 2005, increased to $199.5 million from $180.8 million year over year. Around $85 million of that was from sales in the United States, representing a 12.7-percent increase in sales to that country. The remainder, or approximately $114 million, was in international sales, which represented an 8.7-percent increase in sales.

BD attributed the growth to strong sales of reagents and research instruments, particularly research analyzers and sorters.

BD said company-wide fiscal first-quarter revenue increased 10 percent to $1.4 billion, though "unfavorable" foreign-currency translations cost the firm 1 percent in lost growth.

Spending on R&D increased 11.7 percent in the quarter, jumping to $69.3 million from $62 million year over year, BD said.

The company said profits increased almost 40 percent to $217.9 million, or $.88 per basic share, from $195.4 million, or $.78 per basic share, during the same period last year.

BD did not break out its balance sheet for the quarter.


PerkinElmer's LAS Business Posts 8-Percent Decline in Q4 Revenue

PerkinElmer's Life and Analytical Sciences business unit this week reported revenue of $286.5 million for the fourth quarter of 2005, down 8 percent from $311.9 million in the fourth quarter of 2004.

The company attributed the decline to the "longer fiscal period in 2004 versus this year."

PerkinElmer posted total fourth-quarter 2005 revenue of $387.7 million, a 6-percent decrease over $411.6 million in the fourth quarter of 2004.

The company reported net income of $187.8 million, or GAAP earnings per share of $1.45, versus $37.9 million, or $.29 per share in the fourth quarter of 2004. The company said fourth quarter earnings include net divestiture gains of $1.47 per share.

PerkinElmer finalized the divestiture of its aerospace, semiconductor, and fluid-testing businesses during the quarter.

PerkinElmer spent $21 million on R&D during the fourth quarter of 2005, down from $22.3 million in the comparable period of 2004.

As of Jan. 1, PerkinElmer had cash and cash equivalents of $502.3 million.


Caliper Signs Quality-Control Deal with Artel

Caliper Life Sciences and Artel have entered a technology partnership to "strengthen quality assurance for automated liquid delivery systems," Artel announced this week.

The collaboration involves using Artel's multichannel verification system to test Caliper's Sciclone and RapidPlate automated handlers.

The partnership "gives end-users the option to optimize liquid handling equipment using the same methodology as the equipment manufacturer ... allowing for immediate integration and quality assurance," said Artel.

Financial details of the alliance were not released.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.